Hjb647

Phase 1

Novartis

Hjb647 is one of 20 therapeutic programs targeting Blood Pressure. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Blood PressureRecruiting

Blood PressurePhase 1

Recruiting

Competition

Competitive Landscape

29 competitors in Blood Pressure

#DrugCompanyPhaseTrials

Benicar

Novartis

Phase 3

2 2

Intropin

Pfizer

Preclinical

1 3

Isoproterenol Hydrochloride

Sanofi

Preclinical

1 4

Robinul

Jazz Pharmaceuticals

Preclinical

1 5

Carbocaine

Pfizer

Preclinical

1 6

Ephedrine Sulfate

DDr. Reddys Laboratories, SA

Preclinical

1 7

Atropen

FFresenius Kabi Taiwan Ltd.

Preclinical

1 8

Pitressin

AAultman Health Foundation

Preclinical

1 9

Glypressin

MMallinckrodt

Preclinical

1 10

Iheezo

BB. Braun Medical Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Blood Pressure

NCT07644364

Clinical

Trials by Indication[1]

Blood Pressure1 trial

A Phase 1b, Randomized, Participant- and Investigator- Blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HJB647 Following Single Ascending Dose and Up-titration Multiple Dose Administration in Japanese Healthy Participants With Elevated Blood Pressure and Patients With Hypertension

Recruiting· Novartis logo

Novartis·Phase 1·NCT07644364·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Hjb647. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Hjb647. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: Novartis

Hjb647

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Blood Pressure1 trial

References

Drug Info

Quick Facts

Related News